Dermal Hypersensitivity Reaction to Semaglutide: Two Case Reports - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37026881/
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of antidiabetic agents that work by inducing insulin secretion and inhibiting release of glucagon in a glucose-dependent manner. They are especially promising...
Relevance: In the first case, a 75-year-old woman who had been taking semaglutide for 10 months presented with an eruption on her legs, back, and chest for 3 months duration. Histology showed a subepidermal blister with eosinophils, suggestive of a drug hypersensitivity reaction. In the second case, a 74-year-old white man who had been...
Share
Microbiota-gut-brain axis: relationships among the vagus nerve, gut microbiota, obesity, and diabetes - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37058160/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Because of its enteroendocrine cell-mediated interaction with the gut microbiota, the vagus nerve may provide a potential pathway through which gut microorganisms influence host feeding behavior and metabolic control of physiological and pathological conditions.
Share
Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor Ameliorate Metabolic Disorder and Obesity Induced Cardiomyocyte Injury and Mitochondrial Remodeling - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37047815/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Our study reveals the adverse effects of metabolic disorder- and obesity-induced epicardial fat impairing cardiomyocyte H9c2 function by disturbing the mitochondrial function, such as reducing membrane potential, ROS accumulation, Ca2+ overload, and associated regulator expression. However, most of the dysregulation was...
Share
New insights into the treatment of obesity - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37055715/
Obesity is a chronic, progressive, and relapsing disease with a rising global prevalence associated with increased morbidity and mortality and reduced quality of life. Treatment of obesity requires a comprehensive...
Conclusions/Relevance: these novel agents promise to narrow the gap between the weight-loss effects of behavior interventions, previous pharmacotherapies, and bariatric surgery. In this narrative review, we highlight established and emerging therapeutic treatments for long-term obesity management and position them in a framework according to...
Share
The improved health utility of once-weekly subcutaneous semaglutide 2.4 mg compared with placebo in the STEP 1-4 obesity trials - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37055712/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: Semaglutide 2.4 mg was associated with improvement in health utility scores compared with placebo, reaching statistical significance in STEP 1, 2 and 4.
Share